{
  "docId": "019de513-bbaf-7632-8c51-2e65d00dc762",
  "docSlug": "d61504792622527e2ff1c803565a1f5e",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 42 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 42,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de513-bbaf-7632-8c51-2e65d00dc762/19",
  "deckHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762",
  "deckJsonHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762.json",
  "deckAnchorHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.42,
        "w": 0.552,
        "x": 0.394,
        "y": 0.398
      },
      "kind": "chart",
      "text": "Second Phase 3 (MOJAVE) Efficacy Endpoints: Total Corneal Staining (sign) and Ocular Dryness (symptom) at Day 57",
      "attrs": {
        "x_axis_label": "NOV03, Saline",
        "y_axis_label": "Decrease from Baseline (%)"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3e3fb6c-0f19-4280-9cee-e1b60457b57a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.089,
        "w": 0.089,
        "x": 0.06,
        "y": 0.18
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6f126fe-6b6d-495f-a507-c583601df367",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.309,
        "x": 0.06,
        "y": 0.57
      },
      "kind": "list",
      "text": "In one study, it was found that approximately 86% of patients with DED had MGD involvement.4",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2114858c-a0c5-4acd-aedb-0399887b2641",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.309,
        "x": 0.06,
        "y": 0.47
      },
      "kind": "list",
      "text": "DED is one of the most common ocular surface disorders, with approximately 18M Americans diagnosed with DED. 2,3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d211a8d1-9338-4ffb-babd-8c5ced057eb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.08,
        "x": 0.09,
        "y": 0.74
      },
      "kind": "metric",
      "text": "~24% CAGR",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ba53530-c179-47e3-8dd4-4c55e07730c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.11,
        "x": 0.22,
        "y": 0.74
      },
      "kind": "metric",
      "text": "Expect Double Digit Growth",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec9189e4-757b-4b11-80b0-9ea1b762e34e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.73,
        "x": 0.167,
        "y": 0.183
      },
      "kind": "paragraph",
      "text": "Investigational first in class treatment for Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2da67be6-3c8f-4323-a083-850fe90becc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.73,
        "x": 0.167,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Statistically significant difference of sign and symptom was noted at day 15 and 57 in both Phase 3 studies",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b8477cb-700b-423b-aa99-e4dd4c456c66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.73,
        "x": 0.167,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Consistent statistically significant efficacy, safety and tolerability have now been demonstrated in two Phase 3 studies of NOV03¹ and one Phase 2 study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9caec72b-0d7f-43c8-94cd-69f7675068ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.63,
        "x": 0.158,
        "y": 0.905
      },
      "kind": "source-note",
      "text": "1. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada.\n2. Leonardi, A., Modugno, R. L., & Salami, E. (2021). Allergy and Dry Eye Disease. Ocular immunology and inflammation, 29(6), 1168-1176. https://doi.org/10.1080/09273948.2020.1841804.\n3. 2020 Dry Eye Products Market Report: A global Analysis for 2019 to 2025. Market Scope. Retrieved from https://www.market-scope.com/pages/reports/250/2020-ophthalmic-landscape-report-global-analysis-for-2019-to-2025-april-2021#reports.\n4. Lemp, M. A., Crews, L. A., Bron, A. J., Foulks, G. N., & Sullivan, B. D. (2012). Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea, 31(5), 472-478. doi: 10.1097/ICO.0b013e318225415a.\n5. P-value for the difference in Least Squared Means.\n6. Intent-to-treat.\n7. IQVIA NSP.\n8. Clarivate",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1cc49626-3c7a-4a68-ae9e-f43623f388d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.409,
        "x": 0.045,
        "y": 0.07
      },
      "kind": "title",
      "text": "NOV031: Submitted NDA to FDA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ed6d83b-6b70-432d-a049-14baefc0f40a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "8cc629de-d51b-48a0-84d4-7824f69f25d1",
      "evidence": "chart/bar-vertical: Second Phase 3 (MOJAVE) Efficacy Endpoints",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 15,
      "beatId": "9866f7a1-7d5c-4813-8b8a-f1268197141e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 15-21 propose solutions and highlight the company's portfolio and strategic agreements",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}